These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20630037)

  • 21. Aortic valve allograft structural deterioration is associated with a subset of antibodies to human leukocyte antigens.
    Dignan R; O'Brien M; Hogan P; Thornton A; Fowler K; Byrne D; Stephens F; Harrocks S
    J Heart Valve Dis; 2003 May; 12(3):382-90; discussion 390-1. PubMed ID: 12803340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unexpected anti-HLA-DR and -DQ alloantibodies after nephrectomy of an HLA-DR and -DQ identical first renal transplant.
    Proust B; Kennel A; Ladrière M; Kessler M; Perrier P
    Transpl Immunol; 2009 Jul; 21(3):166-8. PubMed ID: 19341797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
    Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
    Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantation.
    Barocci S; Valente U; Nocera A
    Clin Transplant; 2007; 21(1):47-56. PubMed ID: 17302591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation.
    Morris GP; Phelan DL; Jendrisak MD; Mohanakumar T
    Hum Immunol; 2010 Mar; 71(3):268-73. PubMed ID: 20074605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation.
    Riethmüller S; Ferrari-Lacraz S; Müller MK; Raptis DA; Hadaya K; Rüsi B; Laube G; Schneiter G; Fehr T; Villard J
    Transplantation; 2010 Jul; 90(2):160-7. PubMed ID: 20658760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients.
    Guidicelli G; Anies G; Bachelet T; Dubois V; Moreau JF; Merville P; Couzi L; Taupin JL
    Transpl Immunol; 2013 Dec; 29(1-4):17-21. PubMed ID: 24056164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement-dependent cytotoxicity crossmatch in solid organ transplantation: The gold standard or golden history?
    Tafulo S; Osório E; Mendes C; Liwski R
    Hum Immunol; 2024 Jan; 85(1):110734. PubMed ID: 38030522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation.
    Caro-Oleas JL; González-Escribano MF; Gentil-Govantes MÁ; Acevedo MJ; González-Roncero FM; Blanco GB; Núñez-Roldán A
    Transplantation; 2012 Aug; 94(4):338-44. PubMed ID: 22814330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of HLA class I specific antibodies in patients with failed allografts.
    Mao Q; Terasaki PI; Cai J; El-Awar N; Rebellato L
    Transplantation; 2007 Jan; 83(1):54-61. PubMed ID: 17220791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of Luminex donor-specific crossmatches: data from 165 renal transplants.
    Billen EV; Christiaans MH; van den Berg-Loonen EM
    Tissue Antigens; 2009 Sep; 74(3):205-12. PubMed ID: 19497037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation.
    Goodman RS; Taylor CJ; O'Rourke CM; Lynch A; Bradley JA; Key T
    Transplantation; 2006 May; 81(9):1331-6. PubMed ID: 16699463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney transplantation with positive complement-dependent lymphocytotoxicity crossmatch with negative flow crossmatching and Luminexx donor-specific antibodies.
    Kute VB; Vanikar AV; Gumber MR; Trivedi VB; Shah PR; Patel HV; Balwani MR; Modi PR; Trivedi HL
    Ren Fail; 2013 Aug; 35(7):1027-30. PubMed ID: 23829775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virtual crossmatch in kidney transplantation.
    Piazza A; Ozzella G; Poggi E; Caputo D; Manfreda A; Adorno D
    Transplant Proc; 2014 Sep; 46(7):2195-8. PubMed ID: 25242749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification.
    Gibney EM; Cagle LR; Freed B; Warnell SE; Chan L; Wiseman AC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2625-9. PubMed ID: 16644776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical relevance of pretransplant HLA class II donor-specific antibodies in renal transplantation patients with negative T-cell cytotoxicity crossmatches.
    Song EY; Lee YJ; Hyun J; Kim YS; Ahn C; Ha J; Kim SJ; Park MH
    Ann Lab Med; 2012 Mar; 32(2):139-44. PubMed ID: 22389881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays--single-center experience.
    Mihaylova A; Baltadjieva D; Boneva P; Ivanova M; Penkova K; Marinova D; Mihailova S; Paskalev E; Simeonov P; Naumova E
    Hum Immunol; 2006 Oct; 67(10):787-94. PubMed ID: 17055355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA class I epitopes: recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens.
    El-Awar N; Lee JH; Tarsitani C; Terasaki PI
    Hum Immunol; 2007 Mar; 68(3):170-80. PubMed ID: 17349872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production and characterization of chimeric anti-HLA monoclonal antibodies targeting public epitopes as tools for standardizations of the anti-HLA antibody detection.
    Congy-Jolivet N; Drocourt D; Portet S; Tiraby G; Blancher A
    J Immunol Methods; 2013 Apr; 390(1-2):41-51. PubMed ID: 23352853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA class II DQA and DQB epitopes: recognition of the likely binding sites of HLA-DQ alloantibodies eluted from recombinant HLA-DQ single antigen cell lines.
    El-Awar N; Nguyen A; Almeshari K; Alawami M; Alzayer F; Alharbi M; Sasaki N; Terasaki PI
    Hum Immunol; 2013 Sep; 74(9):1141-52. PubMed ID: 23756161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.